The Klinisch-epidemiologisches Krebsregister Brandenburg-Berlin gGmbH (KKRBB) was founded in 2015 and has performed clinical cancer registration for the states of Brandenburg and Berlin since 01.07.2016; its tasks were expanded on 01.01.2023 to include epidemiological cancer registration. The KKRBB collects comprehensive data on incidence, treatment and course of cancer and provides these scientifically evaluated data to treating physicians, research and health reporting. Funding is provided mainly via case-based register fees, state grants and reimbursements; in the 2024 financial year the KKRBB received total funds of TEUR 9,226.3, of which TEUR 6,112.0 came from statutory health insurance case fees. Organizationally, the KKRBB comprises a central office in Cottbus and five decentralized register offices, employed on average 95 staff in 2024 and closed the Potsdam register office on 31.03.2024.
Die Förderung von Wissenschaft und Forschung sowie die Förderung des öffentlichen Gesundheitswesens.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Cottbus Local Court, HRB 12270 (as of 31 October 2026)
| Name | Type | City |
|---|---|---|
| Renate Kirschner-Schwabe | Geschäftsführer(in) | Cottbus |
Source: German Commercial Register (Handelsregister) Cottbus Local Court, HRB 12270 (as of 31 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | Rohergebnis€9.8M2 | €0 | €8,393,824 | 95 |
| 2023 | €6,156,635 | €0 | €8,250,424 | 98 |
| 2022 | €5,741,430 | €0 | €6,069,919 | 97 |
| 2021 | €5,192,170 | €0 | €5,738,962 | 94 |
| 2020 | €4,868,791 | €0 | €4,837,137 | 81 |
| 2019 | €4,444,668 | €0 | €4,500,803 | 83 |
| 2018 | €3,898,210 | €0 | — | — |
| 2017 | €3,174,156 | €0 | €2,748,202 | — |
| 2016 | €2,218,486 | €0 | €1,499,102 | — |
| 2015 | small company1 | — | €306,616 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Cottbus Local Court, HRB 12270 (as of 31 October 2026)
SGS proderm GmbH
Schenefeld · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
Navitas Life Sciences GmbH
Frankfurt am Main · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
Rayonex Biomedical GmbH
Lennestadt · Forschung und Entwicklung im Bereich Biotechnologie
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €5,733,598 | 94.5% |
| Depreciation | €336,797 | 5.5% |
